Molecules 2011, 16
2256
3.2. Chemistry: Synthesis of 2,9-Dimethoxymethyl-3-diphenylphosphinylboldine (4)
To a solution of 2,9-dimethoxymethyl-3-bromoboldine (3, 135 mg, 0.27 mmol) in dry THF (9 mL),
cooled at −78 °C, n-BuLi (0.50 mL, 1.6 M, 0.80 mmol) was added under an inert atmosphere. After
1 minute, the cooling bath was removed and neat chlorodiphenylphosphine (0.25 mL, 0.81 mmol) was
added dropwise. The mixture was further stirred at room temperature for 1 hour. A saturated NH4Cl
solution (10 mL) was then added for quenching. The organic phase was separated, dried over
anhydrous Na2SO4 and the solvent was removed under reduced pressure at 40 °C. The raw product
was chromatographed (silica gel 0.040–0.063 mm, Merck) employing a mixture of CHCl3/MeOH =
1
99/1 as eluting solvent. Yield: 100 mg (0.16 mmol, 60% yield). H-NMR (CDCl3) : 2.51 (3H, s, N-
CH3), 3.12 (3H, s, 2-OCH3), 3.50 (3H, s, 1-OCH3), 3.55 (3H, s, 9-OCH3), 3.85 (1H, d, J = 4.9 Hz,
2-OCH2O-), 3.88 (3H, s, 10-OCH3), 4.78 (1H, d, J = 4.9 Hz, 2-OCH2O-), 5.28 (2H, s, 9-OCH2O-),
7.06 (1H, s, H-8), 7.40–7.55 (6H, m, Ar-Hmeta + Ar-Hpara), 7.67 (1H, dd, J = 7.8, 1.4 Hz, Ar-Hortho),
7.70 (1H, dd, J = 7.8, 1.5 Hz, Ar-Hortho), 7.78 (1H, dd, J = 7.5, 1.5 Hz, Ar-Hortho), 7.81 (1H, dd,
13
J = 7.4, 1.6 Hz, Ar-Hortho), 7.97 (1H, s, H-11); C-NMR (CDCl3) : 27.8 (C-4), 33.6 (C-7), 43.6 (N-
CH3), 52.6 (C-5), 56.2 (10-OCH3), 56.3 (9-OCH3), 57.2 (2-OCH3), 60.2 (1-OCH3), 63.3 (C-6a), 95.2
(9-OCH2O-), 99.1 (2-OCH2O-), 112.6 (C-11), 115.0 (C-8), 121.3 (C-3), 124.7 (C-11a), 128.2 (Ar-
Cmeta), 128.3 (Ar-Cmeta), 128.4 (Ar-Cmeta), 128.5 (Ar-Cmeta), 130.1 (C-3a), 130.6 (Ar-Cortho), 130.7 (Ar-
Cortho), 130.8 (Ar-Cpara), 131.4 (2C, Ar-Cpara + Ar-Cortho), 131.5 (Ar-Cortho), 132.4 (C-1a), 133.9 (O=P-
31
C), 135.0 (O=P-C), 146.6 (C-9), 147.5 (C-1), 148.2 (C-10), 151.9 (C-2); P-NMR (CDCl3) : 29.1;
HRMS (CI) Found: m/z 616.2481 (M+H+), Calcd. for C35H39NO7P: m/z 616.2459.
3.3. Cell Lines
The experimental cell cultures were obtained from the American Type Culture Collection
(Rockville, MD, USA). MCF-7 and MDA-MB-231 cells were grown in DMEM-F12 medium
containing 10% FCS, 100 U/mL penicillin, 100 µg/mL streptomycin and 1 mM glutamine. DHF
dermal human fibroblast cells were grown in DMEM-F12 medium containing 10% FCS, 100 U/mL
penicillin, 100 µg/mL streptomycin and 1 mM glutamine. Cells were seeded into 96 well microtiter
plates in 100 µL at plating density of 3 × 103 cells/well. After 24 h of incubation at 37 °C in a
humidified 5% CO2: 95% air mixture to allow cell attachment, the cells were treated with different
concentrations of drugs [boldine (1) and derivatives 2–4] and incubated for 72 h under the same
conditions. Stock solutions of compounds were prepared in ethanol and the final concentration of this
solvent was kept constant at 1%. Control cultures received 1% ethanol alone.
3.4. In vitro Growth Inhibition Assay
The sulforhodamine B assay was used according to the method of Skehan et al. [8] with some
modifications [9]. Briefly, the cells were set up 3 × 103 cells per well of a 96-well, flat-bottomed
200 μL microplate. Cells were incubated at 37 °C in a humidified 5% CO2 / 95% air mixture and
treated with the compounds at different concentrations for 72 hours. At the end of the drug exposure,
cells were fixed with 50% trichloroacetic acid (TCA) at 4 °C (TCA final concentration 10%). After
washing with distilled water, cells were stained with 0.1% sulforhodamine B, dissolved in 1% acetic